[The efficacy of eprazinone dihydrochloride (Eftapan) in double-blind studies].
The excellent properties of the new substance eprazinone-dihydrochloride (Eftapan) was demonstrated in a double-blind trial. This agent showed marked secretolytic and bronchial spasmodic properties, further antitussive action and pain relief in the bronchial system. These effects were proven with the parameters of pulmonary function. The substance didn't show any side effect.
D000328:Adult; D000368:Aged; D001991:Bronchitis / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D010919:Placebos; D011427:Propiophenones / Q000627:therapeutic use*; D012129:Respiratory Function Tests; D013183:Sputum / Q000032:analysis
D010879:Piperazines; D010919:Placebos; D011427:Propiophenones; C007608:eprazinone
Die Wirksamkeit von Eprazinon-dihydrochlorid (Eftapan) in der Doppelblind-Studie.